• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸腔积液患者三个月内死亡率的预测因素。

Predictors of mortality within three months in the patients with malignant pleural effusion.

机构信息

Department of Thoracic Surgery, Firat University Medical Faculty, Elaziğ, Turkey.

出版信息

Eur J Intern Med. 2010 Feb;21(1):30-4. doi: 10.1016/j.ejim.2009.09.012.

DOI:10.1016/j.ejim.2009.09.012
PMID:20122610
Abstract

BACKGROUND

Malignant pleural effusion (MPE) has a limited life expectancy (3-12 months). We investigated the predictors of the early mortality (EM) within three months.

METHODS

The patients were retrospectively grouped according to the death within three months (Group I) and survival more than three months (Group II). Demographical, clinical, and biochemical parameters in the fluid were analysed to determine their effects on the EM. The 30-day response rate of talc pleurodesis was investigated.

RESULTS

The study included 85 patients (Group I/Group II=40/45). The patients in Group I died within a median of 28 days. Twenty-six patients in Group II died in a median of 205, but 19 were still alive (median 200 days). The median survival was longer in renal cell, colorectal, breast, liver, ovarian and oropharynx carcinoma, and mesothelioma. Sixty-two patients (63%) underwent talc pleurodesis, which prevented the fluid reaccumulation (p=0.04). The significant factors of the EM in the univariate analysis were the presence of high-risk tumors (lung, stomach, soft tissue, bladder, esophagus, prostate, cervix, and lymphoma), the low Karnofsky performance score (KPS) (p<0.0001), the low pH value of the fluid (p=0.05), and the low concentration of glucose (p=0.01), total protein (p<0.0001), and albumin (p<0.0001) in the fluid. According to the multivariate analysis high-risk tumors (p=0.03), a lower KPS (p<0.001), and glucose value (p=0.04) were the predictors of the EM.

CONCLUSION

Talc pleurodesis prevents the fluid reaccumulation. High-risk tumors, a poor performance status, and lower pleural fluid glucose concentration are predictors of the EM within three months in the patients with a MPE.

摘要

背景

恶性胸腔积液(MPE)的预期寿命有限(3-12 个月)。我们研究了三个月内早期死亡(EM)的预测因素。

方法

根据三个月内死亡(I 组)和存活超过三个月(II 组),回顾性地将患者分组。分析胸腔积液中的人口统计学、临床和生化参数,以确定它们对 EM 的影响。研究滑石粉胸膜固定术的 30 天反应率。

结果

该研究包括 85 名患者(I 组/II 组=40/45)。I 组患者中位死亡时间为 28 天。II 组中有 26 名患者中位死亡时间为 205 天,但仍有 19 名患者存活(中位时间 200 天)。肾细胞癌、结直肠癌、乳腺癌、肝癌、卵巢癌和口咽癌以及间皮瘤患者的中位生存期较长。62 名患者(63%)接受了滑石粉胸膜固定术,这可以防止胸腔积液再积聚(p=0.04)。单因素分析中,EM 的显著因素包括高危肿瘤(肺、胃、软组织、膀胱、食管、前列腺、子宫颈和淋巴瘤)、低卡氏功能状态评分(KPS)(p<0.0001)、胸腔积液 pH 值低(p=0.05)和胸腔积液葡萄糖浓度低(p=0.01)、总蛋白(p<0.0001)和白蛋白(p<0.0001)。多因素分析显示,高危肿瘤(p=0.03)、KPS 降低(p<0.001)和葡萄糖值降低(p=0.04)是 MPE 患者三个月内 EM 的预测因素。

结论

滑石粉胸膜固定术可防止胸腔积液再积聚。高危肿瘤、较差的功能状态和较低的胸腔积液葡萄糖浓度是 MPE 患者三个月内 EM 的预测因素。

相似文献

1
Predictors of mortality within three months in the patients with malignant pleural effusion.恶性胸腔积液患者三个月内死亡率的预测因素。
Eur J Intern Med. 2010 Feb;21(1):30-4. doi: 10.1016/j.ejim.2009.09.012.
2
Prognostic significance of pleural fluid data in patients with malignant effusion.恶性胸腔积液患者胸腔积液数据的预后意义
Eur J Intern Med. 2008 Jul;19(5):334-9. doi: 10.1016/j.ejim.2007.09.014. Epub 2007 Nov 8.
3
Predictors of talc pleurodesis outcome in patients with malignant pleural effusions.恶性胸腔积液患者滑石粉胸膜固定术预后的预测因素
Lung Cancer. 2008 Oct;62(1):139-44. doi: 10.1016/j.lungcan.2008.02.017. Epub 2008 Apr 9.
4
Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.滑石粉胸膜固定术作为恶性胸腔积液患者的姑息性手术。影响生存的因素分析。
Anticancer Res. 2012 Nov;32(11):5071-4.
5
Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma.胸腔积液pH值对乳腺癌患者胸腔镜机械性胸膜固定术疗效的影响
Eur J Cardiothorac Surg. 2004 Aug;26(2):432-6. doi: 10.1016/j.ejcts.2004.03.010.
6
Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.滑石粉喷洒术与滑石粉浆治疗恶性胸腔积液的前瞻性对照研究。
Eur J Cardiothorac Surg. 2006 Dec;30(6):827-32. doi: 10.1016/j.ejcts.2006.10.002.
7
Bedside talc pleurodesis for malignant pleural effusion: factors affecting success.床边滑石粉胸膜固定术治疗恶性胸腔积液:影响成功的因素
Ann Surg Oncol. 2009 Mar;16(3):745-50. doi: 10.1245/s10434-008-0263-x. Epub 2008 Dec 31.
8
Video-assisted thoracoscopic pleurodesis for malignant pleural effusions.电视辅助胸腔镜胸膜固定术治疗恶性胸腔积液
Acta Chir Hung. 1999;38(2):155-7.
9
Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.长期留置胸膜导管(PleurX)用于不适宜滑石粉胸膜固定术的恶性胸腔积液。
Eur J Surg Oncol. 2009 May;35(5):546-51. doi: 10.1016/j.ejso.2008.06.009. Epub 2008 Jul 21.
10
[Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to non-small cell lung cancer].[电视胸腔镜手术与胸腔闭式引流术在非小细胞肺癌所致恶性胸腔积液综合治疗中的对比研究]
Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):1023-6.

引用本文的文献

1
Indwelling tunneled pleural catheter infections and host related factors.留置隧道式胸腔导管感染与宿主相关因素
Respir Med. 2024 Apr;224:107579. doi: 10.1016/j.rmed.2024.107579. Epub 2024 Feb 24.
2
[Risk and Mortality Factors for Pleural Effusions Requiring Diagnostic Thoracentesis].[需要诊断性胸腔穿刺术的胸腔积液的风险和死亡因素]
Open Respir Arch. 2022 Sep 6;4(4):100201. doi: 10.1016/j.opresp.2022.100201. eCollection 2022 Oct-Dec.
3
A Novel Clinical Prognostic Model for Breast Cancer Patients with Malignant Pleural Effusion: Avoiding Chemotherapy in Low-Risk Groups?
一种用于恶性胸腔积液乳腺癌患者的新型临床预后模型:低风险组可避免化疗?
Cancer Manag Res. 2023 May 11;15:409-422. doi: 10.2147/CMAR.S409918. eCollection 2023.
4
Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis.恶性胸腔积液患者的预后生物标志物:一项系统评价和荟萃分析。
Cancer Cell Int. 2022 Feb 24;22(1):99. doi: 10.1186/s12935-022-02518-w.
5
The Value of Cytology in the Evaluation of Malignant Pericardial Effusions: A Systematic Review.细胞学检查在恶性心包积液评估中的价值:一项系统评价
Diagnostics (Basel). 2022 Feb 1;12(2):367. doi: 10.3390/diagnostics12020367.
6
Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.乳腺癌和肺癌胸腔积液生存评分模型:改善恶性胸腔积液和转移患者的生存预测。
Chest. 2021 Sep;160(3):1075-1094. doi: 10.1016/j.chest.2021.03.059. Epub 2021 May 11.
7
Predicting the survival in patients with malignant pleural effusion undergoing indwelling pleural catheter insertion.预测接受胸腔置管术的恶性胸腔积液患者的生存率。
Ann Thorac Med. 2020 Oct-Dec;15(4):223-229. doi: 10.4103/atm.ATM_289_20. Epub 2020 Oct 10.
8
Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre's ten years of experience.留置胸膜导管治疗恶性肿瘤相关性胸腔积液:单中心十年经验报告。
BMC Pulm Med. 2019 Dec 2;19(1):232. doi: 10.1186/s12890-019-1002-8.
9
Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer.人表皮生长因子受体2(Her-2)过表达对转移性乳腺癌患者生存的影响
Asian Pac J Cancer Prev. 2017 Oct 26;18(10):2673-2678. doi: 10.22034/APJCP.2017.18.10.2673.
10
Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.血管内皮生长因子及胸腔积液中的蛋白水平用于鉴别恶性与良性胸腔积液
Oncol Lett. 2017 Sep;14(3):3657-3662. doi: 10.3892/ol.2017.6631. Epub 2017 Jul 20.